Noncoding RNAs in vascular inflammation and atherosclerosis: Recent advances toward therapeutic applications

Current Opinion in Lipidology

Volumn 25, Issue 5, 2014, Pages 380-386

  Cochain, Clément ^a   Zernecke, Alma ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Atherosclerosis; Endothelial cells; Long noncoding RNAs; Macrophages; MicroRNA

Indexed keywords

CYTOKINE; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 126; MICRORNA 155; MICRORNA 33; MICRORNA 342; MICRORNA 92A; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ATHEROSCLEROSIS; CELL FUNCTION; CELL METABOLISM; CELL POLARITY; CHOLESTEROL METABOLISM; CYTOKINE PRODUCTION; DRUG TARGETING; ENDOTHELIUM CELL; FOAM CELL; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VASCULITIS; ANIMAL; GENETICS; LIPID METABOLISM; METABOLISM; MOUSE; PATHOLOGY;

ANIMALIA; MURINAE;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPID METABOLISM; MACROPHAGES; MICE; MICRORNAS; RNA, UNTRANSLATED;

EID: 84921437277     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000108     Document Type: Review

References (52)

1. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol 2014; 9: 73-102.
2. Aryal B, Rotllan N, Fernandez-Hernando C. Noncoding RNAs and atherosclerosis. Curr Atheroscler Rep 2014; 16: 407.
3. Albinsson S, Sward K. Targeting smooth muscle microRNAs for therapeutic benefit in vascular disease. Pharmacol Res 2013; 75: 28-36.
4. Neth P, Nazari-Jahantigh M, Schober A, Weber C. MicroRNAs in flow-dependent vascular remodelling. Cardiovasc Res 2013; 99: 294-303.
5. Boon RA, Hergenreider E, Dimmeler S. Atheroprotective mechanisms of shear stress-regulated microRNAs. Thromb Haemost 2012; 108: 616-620.
6. Zernecke A. MicroRNAs in the regulation of immune cell functions-implications for atherosclerotic vascular disease. Thromb Haemost 2012; 107: 626-633.
7. Busch M, Zernecke A. microRNAs in the regulation of dendritic cell functions in inflammation and atherosclerosis. J Mol Med (Berl) 2012; 90: 877-885.
8. Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014; 114: 345-353.
9. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14: 475-488.
10. Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev 2013; 93: 1317-1542.
11. Davies PF, Civelek M, Fang Y, Fleming I. The atherosusceptible endothelium: Endothelial phenotypes in complex haemodynamic shear stress regions in vivo. Cardiovasc Res 2013; 99: 315-327.
12. Jain MK, Sangwung P, Hamik A. Regulation of an inflammatory disease: Kruppel-like factors and atherosclerosis. Arterioscl Thromb Vasc Biol 2014; 34: 499-508.
13. Ni CW, Qiu H, Jo H. MicroRNA-663 upregulated by oscillatory shear stress plays a role in inflammatory response of endothelial cells. Am J Physiol Heart Circ Physiol 2011; 300: H1762-1769.
14. Li P, Zhu N, Yi B, et al. MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ Res 2013; 113: 1117-1127.
15. Son DJ, Kumar S, Takabe W, et al. The atypical mechanosensitive microRNA- 712 derived from preribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 2013; 4: 3000.
16. Wu W, Xiao H, Laguna-Fernandez A, et al. Flow-dependent regulation of Kruppel-like factor 2 is mediated by microRNA-92a. Circulation 2011; 124: 633-641.
17. Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscl Thromb Vasc Biol 2012; 32: 979-987.
18. Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014; 114: 434-443.
19. Liao X, Sharma N, Kapadia F, et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest 2011; 121: 2736-2749.
20. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-1713.
21. Hinkel R, Penzkofer D, Zuhlke S, et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013; 128: 1066-1075.
22. Hergenreider E, Heydt S, Treguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012; 14: 249-256.
23. Sun X, Icli B, Wara AK, et al. MicroRNA-181b regulates NF-kB-mediated vascular inflammation. J Clin Invest 2012; 122: 1973-1990.
24. Sun X, He S, Wara AK, et al. Systemic delivery of microRNA-181b inhibits nuclear factor-kB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014; 114: 32-40.
25. Cheng HS, Sivachandran N, Lau A, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 2013; 5: 949-966.
26. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: Ra81.
27. Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105: 1516-1521.
28. Sun C, Alkhoury K, Wang YI, et al. IRF-1 and miRNA126 modulate VCAM-1 expression in response to a high-fat meal. Circ Res 2012; 111: 1054-1064.
29. Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014; 20: 368-376.
30. Sun HX, Zeng DY, Li RT, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 2012; 60: 1407-1414.
31. Nazari-Jahantigh M, Wei Y, Noels H, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012; 122: 4190-4202.
32. Du F, Yu F, Wang Y, et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein Edeficient mice. Arterioscl Thromb Vasc Biol 2014; 34: 759-767.
33. Donners MM, Wolfs IM, Stoger LJ, et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 2012; 7: E35877.
34. Zhu J, Chen T, Yang L, et al. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One 2012; 7: E46551.
35. Wei Y, Nazari-Jahantigh M, Chan L, et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155- dependent pathway during atherosclerosis. Circulation 2013; 127: 1609-1619.
36. Arranz A, Doxaki C, Vergadi E, et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci U S A 2012; 109: 9517-9522.
37. Fernandez-Hernando C, Ackah E, Yu J, et al. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab 2007; 6: 446-457.
38. Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328: 1570-1573.
39. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007; 117: 3900-3908.
40. Westerterp M, Murphy AJ, Wang M, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res 2013; 112: 1456-1465.
41. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121: 2921-2931.
42. Horie T, Baba O, Kuwabara Y, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc 2012; 1: E003376.
43. Rotllan N, Ramirez CM, Aryal B, et al. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice-brief report. Arterioscl Thromb Vasc Biol 2013; 33: 1973-1977.
44. Marquart TJ, Wu J, Lusis AJ, Baldan A. AntimiR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscl Thromb Vasc Biol 2013; 33: 455-458.
45. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478: 404-407.
46. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012; 81: 145-166.
47. Geisler S, Coller J. RNA in unexpected places: Long noncoding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013; 14: 699-712.
48. Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 2014; 114: 1389-1397.
49. Carpenter S, Aiello D, Atianand MK, et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science 2013; 341: 789-792.
50. Wang P, Xue Y, Han Y, et al. The STAT3-binding long noncoding RNA lnc- DC controls human dendritic cell differentiation. Science 2014; 344: 310-313.
51. Manthey HD, Zernecke A. Dendritic cells in atherosclerosis: Functions in immune regulation and beyond. Thromb Haemost 2011; 106: 772-778.
52. Leung A, Trac C, Jin W, et al. Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ Res 2013; 113: 266-278.